IDEXX Laboratories, Inc. (IDXX) Shares Bought by Bbva Compass Bancshares Inc.

Bbva Compass Bancshares Inc. lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 18.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,672 shares of the company’s stock after buying an additional 408 shares during the quarter. Bbva Compass Bancshares Inc.’s holdings in IDEXX Laboratories were worth $667,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Valeo Financial Advisors LLC purchased a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at about $134,000. Rehmann Capital Advisory Group raised its holdings in shares of IDEXX Laboratories by 44.9% during the 2nd quarter. Rehmann Capital Advisory Group now owns 668 shares of the company’s stock valued at $146,000 after buying an additional 207 shares during the period. HMS Capital Management LLC purchased a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at about $205,000. Financial Counselors Inc. purchased a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at about $216,000. Finally, Beaumont Financial Partners LLC purchased a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at about $216,000. Institutional investors and hedge funds own 91.27% of the company’s stock.

IDXX stock opened at $209.67 on Friday. IDEXX Laboratories, Inc. has a 52-week low of $146.09 and a 52-week high of $256.22. The company has a market cap of $17.44 billion, a price-to-earnings ratio of 63.92, a price-to-earnings-growth ratio of 2.57 and a beta of 0.82.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Thursday, November 1st. The company reported $1.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.97 by $0.08. IDEXX Laboratories had a negative return on equity of 994.76% and a net margin of 15.19%. The company had revenue of $545.00 million for the quarter, compared to the consensus estimate of $545.66 million. During the same period in the previous year, the business earned $0.76 EPS. IDEXX Laboratories’s revenue for the quarter was up 10.8% compared to the same quarter last year. As a group, equities analysts anticipate that IDEXX Laboratories, Inc. will post 4.19 earnings per share for the current fiscal year.

In other IDEXX Laboratories news, Chairman Jonathan W. Ayers sold 30,000 shares of IDEXX Laboratories stock in a transaction that occurred on Thursday, August 23rd. The stock was sold at an average price of $245.50, for a total transaction of $7,365,000.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, VP Jacqueline Studer sold 11,619 shares of IDEXX Laboratories stock in a transaction that occurred on Tuesday, August 21st. The stock was sold at an average price of $244.03, for a total value of $2,835,384.57. Following the sale, the vice president now owns 17,034 shares in the company, valued at $4,156,807.02. The disclosure for this sale can be found here. Insiders have sold a total of 64,844 shares of company stock worth $15,742,129 over the last 90 days. 2.56% of the stock is owned by company insiders.

Several equities research analysts recently commented on IDXX shares. BidaskClub upgraded IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 1st. Credit Suisse Group raised their target price on IDEXX Laboratories from $255.00 to $259.00 and gave the company an “outperform” rating in a report on Friday, August 17th. Bank of America dropped their target price on IDEXX Laboratories from $275.00 to $235.00 and set a “buy” rating on the stock in a report on Friday, November 2nd. Zacks Investment Research downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Monday, August 6th. Finally, Canaccord Genuity dropped their target price on IDEXX Laboratories from $270.00 to $250.00 and set a “buy” rating on the stock in a report on Monday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $252.33.

COPYRIGHT VIOLATION WARNING: This article was reported by WKRB News and is the sole property of of WKRB News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.wkrb13.com/2018/11/09/idexx-laboratories-inc-idxx-shares-bought-by-bbva-compass-bancshares-inc.html.

About IDEXX Laboratories

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Read More: Capital Gains

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply